Drug Profile
Oxybutynin transdermal - AbbVie
Alternative Names: CS 801; Gelnique Gel 10%; Kentera; MM 801; Oxybutynin patch - AbbVie; Oxybutynin topical gel - AbbVie; OxytrolLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Watson Laboratories
- Developer AbbVie; Daiichi Sankyo Company; Meiji Dairies Corporation
- Class Alkynes; Antispasmodics; Carbocyclic acids; Cyclohexanes; Diethylamines; Esters; Mandelic acids; Skin disorder therapies; Small molecules
- Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Overactive bladder
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 12 Feb 2015 Launched for Overactive bladder in Switzerland, Norway and New Zealand (Transdermal) prior to February 2015
- 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International